Detection of rare cancer mutations from liquid biopsy samples is central to peripheral monitoring but is often challenging due to low amounts of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) present in samples. Digital PCR overcomes this challenge with sensitive and precise detection of extremely low quantities of rare mutations, even in DNA derived from blood plasma or serum samples. The QuantStudio® 3D digital PCR rare mutation solution is optimized for this purpose with the inclusion of TaqMan® SNP Genotyping Assays and analysis software for the detection of rare mutations in cfDNA.  

We are offering up to 5 digital PCR grants for the quantification of rare mutations in cfDNA. Each grant includes the processing of up to 40 samples by scientists from Thermo Fisher Scientific, using the QuantStudio® 3D Digital PCR System and optimized TaqMan® SNP Genotyping Assays.*

Hurry! Application period closes on June 5, 2015

Apply today

*No purchase necessary to enter or receive a grant. To participate in the Applied Biosystems™ QuantStudio™ Cell Free (cfDNA) Grant Program (the “Program”), you must submit your Grant Application (the “Application”) at lifetechnologies.com/cfDNAgrant no later than June 5, 2015 at 11:59 p.m. US Pacific Time. The Program is open only to academic, not-for-profit research institutions or commercial entities located in the United States (excluding Puerto Rico) or Canada (excluding Quebec) whose representative is 21 years of age or older as of May 1, 2015. The person submitting the Application (the “Applicant”) is entering on behalf of their employer, which will be the recipient of the grant (the “Grant Recipient”). Void where this promotion or acceptance of a grant is prohibited or restricted by law or subject to registration or other procedures with which Sponsor may not have undertaken. Healthcare Professionals (term defined in the Official Rules) who receive a grant through this Program may be subject to reporting under the Physician Payments Sunshine Act and state disclosure laws. All grant proposals must be submitted in the English language. Only one Application per laboratory is permitted. Other eligibility restrictions apply. Sponsor will select up to five Grant Recipients from all qualifying entries. Each Grant Recipient will receive cfDNA analysis of DNA provided by the Grant Recipient using the QuantStudio 3D Digital PCR system and data analysis using QuantStudio 3D AnalysisSuite™ Cloud software, all performed by Thermo Fisher Scientific. The approximate retail value of the grant is between US$1,500 and US$3,000, depending upon the number of samples submitted by the Grant Recipient. Winners will be selected by a panel of seven judges comprised of the Sponsor’s employees. Applications will be judged on the following criteria:

  • 60%-Scientific merit or impact and how the study will address an unmet need for cancer mutation analysis in blood plasma or serum samples.
  • 20%-Clearly outlines how the results will be applied for follow-up studies in the specified field of research.
  • 20%-Overall quality of the project abstract

Applications that include personally –identifiable information or patient data, or that propose to disclose personally-identifiable information or patient data, will be excluded from consideration for participation in the Program.

The Applicant’s for the winning Grant Recipients will be notified of their selection on approximately June 8, 2015. The Applicant and/or the Grant Recipient must certify that they are not prohibited by employment, contract, or law from entering or accepting a grant from Sponsor. The complete Official Rules, including grant proposal requirements, are available here. In case of any inconsistency between these short rules and the complete Official Rules, the complete Official Rules will always prevail.